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Abstract: Objective: To review the current published literature on the use of procalcitonin as a
diagnostic and prognostic marker in adult patients with meningitis. Methods: We conducted a
PubMed search to identify all relevant publications regarding the diagnostic and prognostic value of
serum procalcitonin in patients with a known or suspected central nervous system infection. We also
reviewed the bibliographies of all identified manuscripts in an attempt to identify additional relevant
references. Results: A significant body of evidence suggests that serum procalcitonin has a promising
role and can be a useful biomarker in the assessment of patients with meningitis. Conclusions:
Our literature review suggests that data on the role of Cerebrospinal Fluid (CSF) procalcitonin are
limited, whereas serum procalcitonin (S–PCT) is probably a useful tool in the evaluation of patients
with a known or suspected central nervous system infection and can help distinguish between
bacterial and viral meningitis.
Keywords: procalcitonin; bacterial meningitis; viral meningitis; antibiotic therapy; biomarker;
differential diagnosis
1. Introduction
Meningitis is a serious medical condition and can be a major cause of morbidity and mortality.
Early diagnosis and timely initiation of appropriate antibiotic therapy is crucial for reducing mortality
from bacterial meningitis.
The term “biomarker”, as used in daily clinical practice, refers to molecules and biological products
used as markers for the assessment of disease progression or as indicators for the presence of an
abnormal clinical state. Biomarkers can be specific cells or genes, gene products, enzymes or hormones,
have characteristic defined biological properties, and can be detected and measured in biological
fluids (plasma, serum, cerebrospinal fluid, bronchoalveolar lavage) or body tissues. More than
178 biomarkers have been identified in the field of sepsis, but none seem to have sufficient specificity
or sensitivity for routine use in daily clinical practice [1] and some require considerable time, effort,
and costs to measure. In addition, the reliability and validity of certain proposed biomarkers have
not been thoroughly tested [2]. Procalcitonin (PCT) and C-reactive Protein (CRP) are the biomarkers
most commonly used, but have a limited ability to distinguish sepsis from other inflammatory and
non-inflammatory states or to predict outcomes.
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Serum procalcitonin (S–PCT) has been used as biomarker in sepsis because S–PCT levels are
elevated in bacterial, parasitic, or fungal infections, while they remain normal or only slightly elevated
in viral infections. Because early recognition of viral versus bacterial meningitis is critical for the prompt
initiation of treatment to improve prognosis, a reliable method distinguishing bacterial from viral
meningitis could help clinicians limit inappropriate antibiotic treatment. This review was conducted
to evaluate the current knowledge on the use of S–PCT as a tool for the diagnosis of meningitis and for
distinguishing bacterial meningitis (BM) from viral meningitis (VM).
2. Methods
To identify relevant publications of interest, we conducted a PubMed search on 24 May 2018
using the terms ‘procalcitonin and meningitis’ as “Title/Abstract” or as “MeSH Terms”. Because
“Procalcitonin” is not a “Mesh Term” in PubMed, we also used the term “Calcitonin” in “Mesh Terms”
during the search. The structure of the search in the “Search details” window of the PubMed website
was (procalcitonin [Title/Abstract] OR “calcitonin” [MeSH Terms]) AND (meningitis [Title/Abstract]
OR “meningitis” [MeSH Terms]). For the purposes of this review, we then limited the search to
“Humans” and only considered manuscripts presenting data on adults. We also reviewed the
bibliographies of all identified manuscripts to identify additional relevant publications. For the
purposes of this review, we included all types of publications, including case reports, case series,
and review articles, regardless of publication date. Publications in languages other than English were
included only if they had a meaningful detailed abstract in English.
3. Results
The PubMed literature search generated 157 references, but the number of references was reduced
to 125 after limiting the search to “Humans”. After further evaluation, 38 publications were included
in this review.
In a prospective study published in 1999, Viallon et al. evaluated 105 emergency department
patients admitted with suspected meningitis. Based on clinical findings, gram staining, cultures,
and Cerebrospinal Fluid (CSF) chemical analysis, 23 patients had bacterial meningitis, 57 had viral
meningitis, and meningitis was ruled out in 25 patients. Although two patients with previous antibiotic
therapy had S–PCT levels of <0.5, S–PCT was the best marker for differentiating between bacterial
and viral meningitis: Using S–PCT of >0.2 ng/mL as the threshold, S–PCT sensitivity and specificity
approaches 100% for the diagnosis of acute bacterial meningitis [3].
A prospective study published by Schwarz in 2000 included 30 patients with meningitis (16 with
acute bacterial and 14 with abacterial meningitis) and assessed whether S–PCT levels were elevated
in patients with bacterial meningitis. Results of the study showed that, although false negative
results can occur, S–PCT is a useful variable for distinguishing bacterial from non-bacterial meningitis:
Because S–PCT levels do not increase in cases of viral meningitis, even with viral sepsis, increased
S–PCT levels indicated bacterial origins of an infection with high specificity [4].
In 2000, Viallon et al. published the results of a prospective study on 179 patients admitted to
the emergency department on suspicion of meningitis. Of those, 32 patients had bacterial meningitis
and 90 had viral meningitis, whereas 57 patients did not have meningitis. The authors assessed the
role of CSF parameters (cytology, protein, glucose, lactate) and serum parameters (CRP, S–PCT) for
differentiating between bacterial and viral meningitis, and demonstrated that S–PCT was the most
discriminant variable, using a threshold value of 0.93 ng/mL in their population [5].
Shimetani et al. reported extremely high CSF CRP levels in patients with bacterial meningitis,
but only in 10% of patients with viral meningitis. Among patients with bacterial meningitis, S–PCT
levels were more elevated in those with a more serious infection. PCT levels in CSF did not differ
significantly between patients with bacterial, viral, or mycotic meningitis. However, S–PCT levels
were very high in all bacterial meningitis patients, especially in the most serious cases [6].
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A report by Hoffmann et al., published in 2001, assessed S–PCT levels in 12 adult patients with
meningitis and suggested that S–PCT has limited diagnostic value in adults with bacterial meningitis,
especially in cases with unusual agents or nosocomial origin. Increased S–PCT levels in bacterial
meningitis may indicate the presence of bacterial inflammation outside the Central Nervous System
(CNS) [7].
A review by O’Connor published in 2001 included manuscripts published from 1990–2001
to assess the diagnostic usefulness of S–PCT in critical illness. This publication concluded that,
although there is debate regarding the superiority of S–PCT as a sepsis biomarker compared to other
biomarkers, a number of studies support the usefulness of S–PCT in differentiating between bacterial
and viral meningitis [8].
A prospective study on 45 adult patients with CNS infection (20 with bacterial meningitis and 25
with tick-borne encephalitis), published in 2001, evaluated the role of S–PCT and CSF procalcitonin
in differentiating acute bacterial vs. viral meningitis. Median S–PCT level was 6.45 ng/mL
(0.25–43.76 ng/mL) in patients with bacterial meningitis vs. 0.27 ng/mL (0.05–0.44 ng/mL) in patients
with viral meningitis, and the authors concluded that S–PCT and CSF PCT concentrations >0.5 ng/mL
seem to be reliable indicator of bacterial CNS infection [9].
A study by Martinez et al. in 2002 attempted to evaluate the role of S–PCT monitoring in the
differential diagnosis of ventriculitis in adult Intensive Care Unit (ICU) patients. The study included
15 consecutive ICU patients with ventriculitis and a ventricular catheter in place, and compared these
data with 10 patients with community-acquired bacterial meningitis. The authors concluded that,
in contrast to bacterial meningitis, monitoring of S–PCT alone is not helpful for the diagnosis of
ventriculitis [10].
A case report published in 2004 presented the case of a 73-year-old woman with progressively
worsening headaches, nausea, vomiting, and neck stiffness. As her clinical condition deteriorated,
she developed diffuse brain edema and hydrocephalus, requiring external ventricular drainage (EVD)
and admission to a neurologic ICU, with a subsequent diagnosis of severe post-myelographic chemical
meningitis. The authors compared CSF and serum inflammatory markers of this patient versus seven
patients with proven bacterial meningitis and concluded that S–PCT may be useful in differentiating
between bacterial and chemical causes of CNS inflammation [11].
A study by Kepa et al. assessed the role of CSF PCT and S–PCT levels in the differential diagnosis
of adults with CNS infections. The study included 17 patients with bacterial meningoencephalitis and
16 patients with lymphocytic meningitis and showed that CSF and plasma PCT levels were significantly
different between these two patient groups. These results supported the usefulness of measuring
plasma PCT levels in the differential diagnosis of CNS infections in adults. With regards to the role
of CSF PCT, the authors concluded that CSF PCT levels are less important for differential diagnosis,
but correlate with the severity of bacterial meningoencephalitis and can be taken into consideration
when predicting prognosis and outcomes [12].
In 2005, a study by Viallon et al. described the change in S–PCT levels during the treatment of
48 patients with community-acquired acute bacterial meningitis. Bacterial infection was documented in
45 patients and initial antibiotic treatment was effective in all patients. Serum PCT levels were measured
on admission and on day two, and showed that S–PCT levels decline rapidly with appropriate antibiotic
therapy. The authors concluded that the rapid decline of S–PCT levels reduces the value of performing
lumbar puncture 48 to 72 h after admission to assess the effectiveness of antibiotic therapy [13].
Ernst and colleagues evaluated serum and CSF procalcitonin levels in patients with dementia
disorders and neuro-inflammation. The study included 40 patients with probable Alzheimer’s
disease, 12 patients with frontotemporal dementia (FTD), 8 patients with dementia with Lewy
bodies (DLB), 12 patients with vascular dementia (VD), 16 patients with acute neuroinflammation,
and 50 non-dementia control patients (18 surgery patients and 32 patients with other neurologic
diseases)and showed that, compared to non-dementia controls, CSF procalcitonin levels were increased
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in patients with dementia diseases and acute neuro-inflammation. In addition, in matched serum
samples, S–PCT levels were elevated in meningitis patients, but not in dementia patients [14].
An observational cohort study by Knudsen et al. included 55 patients with suspected meningitis
and compared the diagnostic value of serum sCD163 levels, CRP, and procalcitonin in bacterial
infection and meningitis and showed that, although elevated serum sCD163 levels seem to be the
most specific biomarker for differentiating between bacterial and non-bacterial disease (specificity 0.91;
sensitivity 0.47), the overall diagnostic accuracy of CRP (Area Under the Curve (AUC) = 0.91) and
PCT (AUC = 0.87) were superior compared to sCD163. The authors concluded that, although PCT and
CRP had very high accuracy for distinguishing between bacterial and viral infection, none of them
were useful as an independent tool for diagnosis in patients presenting with purulent meningitis [15].
A prospective multicenter study, published in 2007, included 151 patients with bacterial or
nonbacterial meningitis and negative initial Gram stains from three teaching hospitals in France and
reported laboratory data, including results of CSF analysis (CSF leukocyte count, percentage of CSF
leukocyte, CSF/blood glucose ratio, CSF protein), serum CRP, and serum PCT, together with clinical
findings and outcomes. The study evaluated the accuracy of laboratory results in differentiating
between bacterial and non-bacterial meningitis in patients with meningitis and a negative gram
stain, and concluded that CSF laboratory results have some role in distinguishing bacterial from
non-bacterial meningitis, whereas serum CRP (AUC 0.81 (95% CI 0.58–0.92) and S–PCT levels (AUC
0.98, 95% CI, 0.83–1.00) are excellent predictors of bacterial meningitis, with S CPT being clearly
superior (p < 0.05) [16].
A prospective study from the Saint-Etienne University Hospital in France collected data from all
patients admitted to the emergency unit with suspected meningitis between 1997 and 2009. Data were
collected on 97 patients with bacterial meningitis and 218 patients with viral meningitis, but, after
62 patients with Bacterial Meningitis (BM) were excluded for various reasons, the study only included
data from 35 patients with BM and negative direct CSF examination. The aim of the study was to
determine the ability of several parameters used for the diagnosis of acute meningitis in differentiating
between bacterial and viral meningitis in adult patients with a negative CSF examination. In this study,
S–PCT had a 95% sensitivity, 100% specificity, and 100% negative predictive value, as well as a 97%
positive predictive value for distinguishing BM versus Viral Meningitis (VM) when using a diagnostic
cut-off level of 0.28 ng/mL (AUC, 0.99; 95% CI, 0.99 to 1) [17].
A prospective study on 36 adult patients with acute meningitis was published in 2012. The aim of
the study was to evaluate the role of serum procalcitonin levels over time during treatment for central
nervous system infections. Serum procalcitonin levels were measured before the initiation of treatment
and 24 and 72 h after treatment started. Results showed that mean PCT levels were higher in patients
who did not improve and that the reduction of serum PCT levels were more significant after 72 h in
patients who improved. The authors emphasized the role of serum PCT levels as a marker for follow
up in treating patients with bacterial meningitis [18].
A study by Choi assessed the value of serum procalcitonin in differentiating post-operative
bacterial meningitis (PBM) versus postoperative aseptic meningitis (PAM) after neurological surgery
and included patients who had cerebrospinal fluid pleocytosis within 14 days of surgery. The study
compared PCT in 14 patients with PBM against 64 patients with PAM and showed that serum PCT
had limited value for diagnosing PBM and serum PCT levels of ≥0.15 ng/mL had 80% specificity.
However, CPT combined with other biomarkers can be a useful adjunct for increasing diagnostic
sensitivity [19].
An observational study by Tian et al., from Guadong, China and published in 2014, investigated
the value of procalcitonin in the discrimination between sepsis and systemic inflammatory response
syndrome (SIRS). The study included patients treated in a neurological intensive care unit and serum
levels of C-reactive protein and S–PCT were evaluated on admission day, on the day of diagnosis
of SIRS or sepsis, and on days three and seven after the diagnosis. Results of the study showed
significant differences in S–PCT levels between groups at all stages of sepsis. The authors concluded
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that S–PCT has significant value as an index for discriminating sepsis from SIRS and in determining
sepsis severity [20].
A study by Abdelkader et al. published in 2014 evaluated 40 patients with suspected acute
meningitis and negative gram stains compared to 10 healthy controls. The goal of the study was to
evaluate the role of S–PCT in differentiating bacterial from aseptic meningitis in patients with negative
cerebrospinal fluid (CSF) examination on admission and after three days of treatment, and to assess the
role of PCT and other inflammatory markers in relation to treatment efficacy. In this study, patients in
the bacterial group had significantly higher serum PCT on admission compared to the aseptic group
(2.49± 2.54 vs. 0.89± 0.69, p < 0. 001), and there was a significant difference in bacterial versus. aseptic
meningitis, even after three days of treatment (1.70 ± 1.58 vs. 0.64 ± 0.51, p < 0.001) [21].
A prospective observational study, published by Shen et al. in 2015, assessed the diagnostic
value of serum and CSF PCT levels in 120 patients with meningitis-like symptoms and showed that
both S–PCT and CSF PCT levels were increased in patients with bacterial meningitis (BM). The area
under the Receiver Operator Characteristic (ROC) curve was 0.96 (CI 0.93–1.00) for S–PCT versus
0.9 (CI 0.83–0.96) for CSF PCT in the diagnosis of BM. When using 0.88 ng/mL as a threshold, S–PCT
had an 87% sensitivity and 100% specificity for the diagnosis of BM. The study concluded that
both S–PCT and CSF PCT have value for the diagnosis of BM, but the diagnostic value of S–PCT is
superior [22].
In another prospective observational study, Omar et al. collected data on CRP, S–PCT, and
CSF cultures every other day in 36 adult patients with severe head trauma and ventriculostomy,
and observed elevated S–PCT concentration in all five patients who developed ventriculostomy-related
infections. Mean serum PCT was <2.0 ng/mL in patients with negative CSF cultures versus 4.18 ng/mL
in patients with positive cultures. The study concluded that an early increase of S–PCT levels is a valid
indicator of bacterial CNS infection in patients with head trauma and External Ventricular Drainage
(EVD) [23].
A retrospective clinical study by Li et al. assessed the diagnostic value of CSF procalcitonin
combined with CSF lactate levels in distinguishing post-neurosurgical bacterial meningitis (PNBM)
from aseptic meningitis in 178 hospitalized patients with suspected PNMB (50 patients with PNBM vs.
128 patients without PNBM). Median (min, max) CSF procalcitonin levels were 0.2 (0–3.1) in patients
with PNBM versus 0 (0–0.5) in patients with non-PNBM (p < 0.001), and ROC analysis revealed a
cut-off value of 0.075 ng/mL (AUC = 0.746, sensitivity 68.0%; specificity 72.7%, p < 0.001) for CSF
procalcitonin. Similarly, median (min, max) CSF lactate levels were 5.3 (2.2–10.6) in patients with
PNBM versus 2.3 (1.2–5.4) in patients with non-PNBM (p < 0.001), and ROC analysis revealed a
cut-off value of 3.45 mmol/L (AUC = 0.943, sensitivity 90.0%; specificity 84.4%, p < 0.001) for CSF
lactate. The study showed that PNBM patients have significantly higher CSF procalcitonin and CSF
lactate levels compared with non-PNBM patients and concluded that CSF lactate and PCT levels
have significant diagnostic value for PNBM, and could be useful in differentiating PNBM from
non-PNBM [24].
A publication by Konstantinidis et al. in 2015 evaluated CSF procalcitonin levels and compared
CSF procalcitonin levels with CSF levels of other established markers of infection, such as CRP,
high-sensitivity CRP, and White Blood Cells (WBC) in 30 ICU, Medicine, Neurology, Hematology,
and Pediatric patients with bacterial (n = 19) or viral (n = 11) meningitis, and in 28 patients with
non-infectious diseases. In this study, CSF PCT levels were 4.714 ± 1.59 ng/mL in bacterial meningitis
versus 0.1327 ± 0.03 ng/mL in patients with viral meningitis versus <0.1 ng/mL in patients with
non-infectious diseases, with the authors concluding that S–PCT can be helpful in distinguishing
bacterial meningitis from viral meningitis and other noninfectious CNS diseases [25].
A meta-analysis published in 2015 by Vikse et al. included nine studies with a total of
725 patients and concluded that serum procalcitonin had a pooled sensitivity of 0.90 (95% CI 0.84–0.94),
a specificity of 0.98 (0.97–0.99), a positive likelihood ratio of 27.3 (8.2–91.1), a negative likelihood ratio
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of 0.13 (0.07–0.26), a diagnostic odds ratio of 287.0 (58.5–1409.0), and, thus, is far superior to CRP for
rapid differentiation between bacterial and viral meningitis [26].
Kim et al. compared S–PCT levels in 26 patients with tuberculosis meningitis versus 70 patients
with BM and 49 patients with VM in a retrospective study and showed that low S–PCT levels
(≤1.27 ng/mL) independently distinguished tuberculosis meningitis from bacterial meningitis, with a
96.2% sensitivity and a 62.9% specificity. However, S–PCT levels were not significantly different in
patients with tuberculosis versus viral meningitis. Logistic regression showed that an S–PCT level
of >0.4 ng/mL was an independent predictor of a poor prognosis in patients with tuberculosis
meningitis and had a negative correlation with Glasgow Coma Scale (GCS) scores at discharge
(r = 0.437, p = 0.026) [27].
A prospective observational study published by Morales-Casado et al. in 2016 assessed the role of
32 clinical and epidemiological variables as predictors of bacterial meningitis in 154 patients aged over
15 years who presented in the Emergency Department with symptoms of acute meningitis. Multivariate
logistic regression showed that four variables (S–PCT, CSF lactate ≥33 mg/dL, CSF glucose <60% of
blood value, and CSF polymorphonuclears ≥50%) were excellent tools for the prediction of bacterial
meningitis; the model using S–PCT ≥0.8 ng/mL and CSF lactate ≥33 mg/dL had an AUC of 0.992,
with a 99% sensitivity and a 98% specificity for predicting bacterial meningitis (95% CI: 0.979–1;
p < 001) [28].
Another prospective observational study by Morales-Casado et al. evaluated the usefulness of
inflammatory markers for the diagnosis of bacterial meningitis in 220 patients and showed that S–PCT
had the highest AUC (0.972; 95% CI, 0.946–0.998; p < 001) for the diagnosis of BM. Using 0.52 ng/mL as
a cutoff, S–PCT had 93% sensitivity and 86% specificity for the diagnosis of BM overall, but sensitivity
was 96% and specificity was 75% in patients >75 years old [29].
In 2016, Wei and colleagues published a systematic review and meta-analysis on the role of
procalcitonin in the diagnosis of bacterial versus non-bacterial meningitis. The review included
twenty-two studies with a total of 2058 patients; diagnostic accuracy of S–PCT and CSF PCT was
assessed using the bivariate model and analysis showed that PCT is a useful biomarker for the
diagnosis of bacterial meningitis: CSF PCT had 0.86 specificity and 0.8 sensitivity, whereas S–PCT had
0.97 specificity and 0.95 sensitivity [30].
A prospective, observational study published in 2016 by Morales Casado et al. evaluated
serum PCT and C-reactive protein as markers for detection of bacterial meningitis in 98 patients
diagnosed with acute meningitis in the emergency department (38 pts with BM, 33 with VM, 15 with
probable VM, and 12 with presumptively diagnosed, partially treated acute meningitis). Data analysis
showed that S–PCT levels were significantly higher in patients with BM (11.47 ± 7.76 ng/mL vs.
0.10 ± 0.15 ng/mL in viral meningitis, p < 0.001). Using 1.1 ng/mL as cutoff, S–PCT as diagnostic tool
achieved 94.6% sensitivity, 72.4% specificity, 95.4% NPV, and 69.2% PPV, and AUC was 0.965 (95% CI,
0.921–1; p < 0.001). Based on these results, the authors concluded that S–PCT performs better than
CRP in the detection of bacterial meningitis [31].
In a prospective observational study published in 2017, Zhang et al. measured S–PCT and CSF
PCT, high-sensitivity C-reactive proteins (Hs-CRP), proteins, chloride, and glucose in three patient
groups: 24 patients with suppurative meningitis, 20 with VM, and 22 with tuberculous meningitis
(TBM). S–PCT values were significantly higher in the suppurative meningitis group, but declined
significantly in suppurative meningitis patients after 72 h and seven days of treatment. In addition,
admission CSF PCT levels were significantly lower in VM compared to TBM and suppurative
meningitis patients, but CSF PCT values did not change significantly with treatment. The authors
concluded that S–PCT changes over time can be useful in evaluating disease progression and response
to treatment in patients with suppurative meningitis [32].
A retrospective clinical study on 80 patients with BM and 58 with VM, published by Park in 2017,
showed that S–PCT >0.12 ng/mL is a significant marker for differentiating BM from VM, and also that
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S–PCT levels >7.26 ng/mL are associated with higher risk of death (OR = 9.09, 95% CI: 1.74–47.12,
p = 0.016) [33].
Last, a prospective observational study published by Li et al. in 2017 included 143 ICU patients
(49 with BM, 25 with TBM, 34 with viral meningitis/encephalitis (VM/E), 15 with autoimmune
encephalitis (AIE), and 20 with non-inflammatory nervous system diseases (NINSD) to assess the
value of CSF PCT, S–PCT and other biomarkers in the diagnosis of BM. In this study, CSF PCT levels
(median, range) were significantly (P < 0.01) higher in BM patients (0.22, 0.13–0.54 ng/mL) compared to
TBM (0.12, 0.07–0.16 ng/mL), VM/E (0.09, 0.07–0.11 ng/mL), AIE (0.06, 0.05–0.10 ng/mL), or NINSD
(0.07, 0.06–0.08 ng/mL) patients. Furthermore, CSF PCT had the highest area under the receiver
operating characteristic curve (AUROC) (0.881; 95% CI 0.810–0.932; cutoff 0.15 ng/mL; sensitivity
69.39%; specificity 91.49%), whereas S–PCT was less useful (AUROC 0.759, 95% CI 0.669–0.849, cutoff
0.19 ng/mL, with sensitivity 67.35% and specificity 75.53% for the diagnosis of BM [34]. Findings
of clinical studies evaluating the role of PCT in patients with known or suspected meningitis are
summarized in Table 1. Quantitative measures, including AUC, sensitivity, specificity, and cut-off
points, reported in clinical studies included in this review are summarized in Table 2.
Table 1. Clinical studies evaluating the role of procalcitonin (PCT) in patients with known or
suspected meningitis.
Reference Origin Study Design Patient Population Findings
[3] St. Etienne,France Prospective study
105 pts (23 with BM, 57 with VM,
25 controls), 54 women, 51 men, mean
age 42 years (range 16–82 years)
S–PCT was the best marker for differentiating
BM vs. VM. with S–PCT > 0.2 ng/mL as the
cutoff, S–PCT sensitivity and specificity
approaches 100% for diagnosing acute BM
[4] Heidelberg,Germany Prospective case series
30 pts (13 men, 17 women), mean age
52 (range, 16–87 years)
S–PCT is useful for distinguishing BM from
VM. Increased S–PCT levels have a high
specificity for bacterial infection
[5] St. Etienne,France Prospective study
179 patients with suspected
meningitis: 32 patients with BM, 90
patients with VM, 57 patients did not
have meningitis
S–PCT is the most discriminant variable for
differentiating BM vs. VM, with a threshold
value 0.93 ng/mL
[6] Saitama, Japan Prospective study
42 patients requiring CSF
examination, 12 patients with
non-inflammatory CNS disease as
controls, 22 men, mean age 37.8 years;
20 women, mean age 38.1 years
CSF PCT levels not significantly different in
BM, VM, or mycotic meningitis. S–PCT >
0.1 mcg/L in all BM patients. AUC and cut-off
values were not reported
[7] Berlin,Germany
Case series, 12 adults
with meningitis
12 pts: 7 men, 5 women, mean age
48.6 years






20 BM patients: 11 men, 9 women,
mean age 55 years; 25 TBE patients:
13 men, 12 women, mean age 49 years
Median S–PCT 6.45 ng/mL (0.25–43.76) in
patients with BM vs. 0.27 ng/mL (0.05–0.44) in
patients with TBE. S–PCT and CSF PCT >
0.5 ng/mL is a reliable indicator of BM
[10] Dresden,Germany Prospective ICU study
11 ventriculitis patients with negative
CSF (6 men, 5 women, mean age
44.3 years), 4 ventriculitis patients
with positive CSF (2 men, 2 women,
mean age 56.2 years), 10 community
BM (7 men, 3 women, mean age
49.4 years)
S–PCT alone is not helpful for diagnosis
of ventriculitis
[11] Munich,Germany




7 ICU BM patients (4 men, 3 women,
mean age 55 years), and one woman
with aseptic, chemical meningitis
S–PCT is useful in differentiating bacterial vs.
chemical CNS inflammation
[12] Poland Observational study,33 adult patients
17 bacterial meningoencephalitis
patients vs. 16 lymphocytic
meningitis patients
CSF PCT and S–PCT significantly higher in BM
vs. lymphocytic meningitis (CSF PCT
0.63 ng/mL vs. 0.23 ng/mL, p < 0.05, S–PCT
9.97 ng/mL vs. 0.27 ng/mL, p < 0.01
[13] St. Etienne,France
Prospective study,
48 BM patients with
S–PCT > 0.5 ng/mL
on admission
48 BM patients: 21 men, 27 women,
mean age 55 years
S–PCT levels declined rapidly with
antibiotic therapy
[14] Borgsdorf,Germany Prospective Study
40 patients with AD, 12 with FTD, 8
with DLB, 12 with VD, 16 with acute
neuroinflammation, 50 controls
Measured S–PCT, CSF PCT. S–PCT elevated in
meningitis. CSF PCT helpful in
diagnosing dementia
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Table 1. Cont.




52 patients (25 men, 27 women) with
suspected meningitis, median age
36 (range, 13–92 years)
S–PCT has a moderate overall accuracy for





133 NBM patients: 66 men, 67 women,
mean age 33 years vs. 18 BM patients:
9 men, 9 women, mean age 52 years






35 patients (17 men, 18 women, mean
age 55 years) with BM, 218 patients
(116 men, 102 women, mean age
35 years) with VM
S–PCT had very high diagnostic value for
distinguishing BM vs. VM
[18] Ahvaz, Iran
Prospective study,
36 patients with acute
meningitis
36 acute meningitis patients: 26 men,
10 women, mean age 38.4 years
S–PCT levels were reduced after 72 h in
patients who improved, but remained higher in





14 patients with BM: 4 men,
10 women, median age 52 (range
44–63) vs. 64 aseptic meningitis
patients: 35 men, 29 women, median
age 47.5 (range 35–61 years)
S–PCT has limited value for diagnosing BM





22 sepsis patients (16 men, 6 women,
mean age 58 years), 22 severe sepsis
patients (17 men, 5 women, mean age
55.4 years), 12 septic shock patients
(5 men, 6 women, mean age
51.9 years), and 48 SIRS patients
(28 men, 20 women, mean age 51.8
years)
Assessed S–PCT for discrimination between
sepsis and SIRS. S–PCT levels were
significantly different between groups at all
stages of sepsis. S–PCT has value for







16 ABM patients (9 men, 7 women,
mean age 39 years) and 24 patients
with acute ASM (21 men, 3 women,
mean age 29 years), 10 controls
(7 men, 3 women, mean age 40 years)
S–PCT significantly higher in BM compared to
ASM patients (2.49 ± 2.54 vs. 0.89 ± 0.69,
p < 0.001). Difference in BM vs. ASM persisted





45 BM patients (30 men, 15 women,
mean age 50) vs. 75 non-BM patients
(55 men, 20 women, mean age
47 years)





36 head trauma patients with EVD
(30 men, 6 women, mean age
32.8 years)
High S–PCT in patients with
ventriculostomy-related infections. Early






50 with PNBM (23 men, 27 women,
median age 42 years) vs. 128 without
PNBM 49 men, 79 women, median
age 42 years)
CSF lactate and PCT have significant
diagnostic value for PNBM and could be useful





19 BM patients (12 men, 7 women,
mean age 41 years) vs. 11 VM patients
(8 men, 3 women, mean age 24 years)
vs. 28 controls (20 men, 8 women,
mean age 30 years)
CSF–PCT is helpful in distinguishing BM from






26 TBM patients (13 men, 13 women,
mean age 57 years) vs. 70 BM patients
(42 men, 28 women, mean age
64 years) vs. 49 VM patients (24 men,
25 women, mean age 40 years)
S–PCT levels not significantly different in TBM
vs. VM, but S–PCT > 0.4 ng/mL was a
predictor of poor prognosis in TBM
[29] Toledo, Spain Prospective,observational study
220 meningitis patients (136 men,
84 women, mean age 30 years)
PCT has high diagnostic powers and
outperforms CRP and leukocytes for the
detection of bacterial meningitis
[28] Toledo, Spain Prospectiveobservational study 154 ED patients over age 15
Logistic regression shows that
S–PCT ≥ 0.8 ng/mL + CSF lactate ≥ 33 mg/dL
are strong predictors of BM (p < 0.001)
[31] Toledo, Spain Prospective,observational study
98 ED patients (66 men, 32 women,
mean age 44 years), 38 BM patients
(mean age 61.5 years), 33 VM patients
(mean age 36 years) 15 with probable
VM, but negative cultures, 12 with
antibiotic treatment and
negative cultures
S–PCT higher in BM vs. VM (11.47 ± 7.76 vs.
0.10 ± 0.15 ng/mL, p < 0.001). S–PCT is
superior to S-CRP for BM detection
[32] Jilin, China Prospectiveobservational study
66 meningitis patients: 37 men,
29 women, mean age 40.21 years
(24 suppurative meningitis, 20 VM,
22 TBM), 20 controls: 11 men,
9 women, mean age 43.05 years
S–PCT is significantly higher in suppurative
meningitis, declined significantly after 72 h and
7 days of treatment. CSF PCT is significantly
lower in VM compared to TBM and
suppurative meningitis.
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Table 1. Cont.





80 patients with BM (49 patients,
31 women, median age 66 years) vs.
58 VM patients (30 men, 28 women,
median age 37 years)
S–PCT levels >0.12 ng/mL are significant




143 ICU patients with
CNS disease
49 BM patients (36 men, 13 women,
median age 43 years) vs. 25 TBM
patients (15 men, 10 women, median
age 42 years) vs. 34 VM patients
(25 men, 9 women, median age
39.5 years) vs. 15 AIE patients (6 men,
9 women, median age 27 years) vs.
20 NINSD (11 men, 9 women, median
age 43 years)
CSF PCT levels were significantly higher in BM
compared to TBM, VM, AIE, or NINSD
ABM = Acute Bacterial Meningitis, AD = Alzheimer’s disease, AIE = Autoimmune Encephalitis, ASM = Aseptic
Meningitis, AUC = Area Under the Curve, AUROC = Area Under The Receiver Operating Characteristic
Curve, BM = Bacterial Meningitis, CI = Confidence Interval, CRP = C-reactive protein, CSF = cerebrospinal
fluid, DLB = Dementia with Lewy bodies, ED = Emergency Department, EVD = External Ventricular Drainage,
FTD = Frontotemporal dementia, LP = Lumbar Puncture, NBM = Nonbacterial Meningitis, NICU = Neurological
Intensive Care Unit, NINSD = Non-Inflammatory Nervous System Disease, NPV = Negative Predictive Value,
PMN = Polymorphonuclear, PNBM = Post-Neurosurgical Bacterial Meningitis, PPV = Positive Predictive Value,
Pts = patients, S–PCT = Serum Procalcitonin, SIRS = Systemic Inflammatory Response Syndrome, Tb = Tuberculosis,
TBE = Tick-Borne Encephalitis, TBM = Tuberculous Meningitis, VD = Vascular Dementia, VM/E = Viral
Meningitis/Encephalitis, VM = Viral Meningitis.
Table 2. Area under the Curve (AUC), sensitivity, specificity, and cut-off points reported in clinical
studies evaluating Serum Procalcitonin (S–PCT) or Cerebrospinal Fluid Procalcitonin (CSF PCT) in
patients with known or suspected meningitis.
Reference Biomarker AUC (95% CI) p Value Cut-off Point Sensitivity Specificity Comments
[3] S–PCT Not reported 0.2 ng/mL 100% 100%
CSF PCT found only in two patients with
hemorrhage. S–PCT sensitivity and specificity
approach 100% for diagnosing acute BM
[4] S–PCT Not reported 0.5 ng/mL 69%(41–89%)
100%
(79–100%)
S–PCT is a useful variable for distinguishing
BM from VM. Increased S–PCT levels have a
high specificity for bacterial infection
[5] S–PCT Not reported 0.93 ng/mL Notreported 100%
S–PCT is the most discriminant variable for
differentiating BM vs. VM
[7] S–PCT Not reported 1 ng/mL 58.3% Notreported











Median S–PCT is significantly higher in BM
(6.45 ng/mL range 0.25–43.76) vs. TBE
(0.27 ng/mL, 0.05–0.44). S–PCT, CSF
PCT > 0.5 ng/mL is a reliable indicator of BM
[10] S–PCT Not reported 1.0 ng/mL 100% 83% S–PCT is not helpful for diagnosis ofventriculitis, but is highly diagnostic for BM
[11] S–PCT Not reported 1.0 ng/mL Notreported
Not
reported
S–PCT is useful in differentiating bacterial vs.
chemical causes of CNS inflammation





CSF PCT and S–PCT are significantly higher
in bacterial meningoencephalitis vs.
lymphocytic meningitis
[13] S–PCT Not reported Not reported Notreported
Not
reported
Rapid S–PCT decline with antibiotic therapy
reduces the value of repeating LP to assess
antibiotic therapy effectiveness







S–PCT levels are elevated in meningitis, but
not in dementia
[15] S–PCT 0.93 (0.64–0.99) 0.25 ng/mL 0.90(0.55–1.0)
0.92
(0.62–1.0)
S–PCT is helpful for differentiating BM vs.











S-CRP and S–PCT are excellent predictors of
BM
[17] S–PCT 0.99 (0.99–1.00) 0.28 ng/mL 97% 100% S–PCT: High diagnostic value fordistinguishing BM vs. VM
[18] S–PCT Not reported Not reported Notreported
Not
reported
S–PCT can be a useful marker for the follow
up of BM patients
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Table 2. Cont.
Reference Biomarker AUC (95% CI) p Value Cut-off Point Sensitivity Specificity Comments
[19] S–PCT 0.617 0.15 ng/mL 50% 80% S–PCT is of limited value for diagnosing BM
[20] S–PCT 0.799 (0.711–0.887) 2 ng/mL 75% 83.3% S–PCT has value for discriminating sepsis vs.SIRS and determining sepsis severity
[21] S–PCT AUC shown, but valuenot reported 1.2 ng/mL 68.8% 83.3%
Admission S–PCT is higher in BM patients
compared to ASM patients (2.49 ± 2.54 vs.
0.89 ± 0.69, p < 0. 001). The difference in BM
vs. ASM persisted after 3 days of therapy
(1.70 ± 1.58 vs. 0.64 ± 0.51, p < 0.001)
[22] S–PCT 0.96 (0.93–1.00) 0.88 ng/mL 87% 100% S–PCT and CSF PCT increased in BM patients.
[23] S–PCT Not reported Not reported Notreported
Not
reported
Mean S–PCT < 2.0 ng/mL in patients with

















CSF lactate and CSF PCT have significant
diagnostic value for PNBM
[25] CSFPCT Not reported Not reported 100% 96.4%
CSF PCT 4.71 ± 1.59 ng/mL in BM,
0.13 ± 0.03 ng/mL in VM, <0.1 in patients
with non-infectious disease
[27] S–PCT 0.876 (0.688–0.972) 1.27 ng/mL 96.2%(80.4–99.9)
62.9%
(50.5–74.1)
S–PCT useful for distinguishing TBM from
BM. S–PCT > 0.4 ng/mL is predictor of poor
outcome in TBM












The combination of S–PCT ≥ 0.8 ng/mL +
CSF lactate ≥ 33 mg/dL has excellent
diagnostic value for predicting BM
[31] S–PCT 0.965 (0.921–1),p < 0.001 1.1 ng/mL 94.6% 72.4%
S–PCT significantly higher in BM vs. VM
(11.47 ± 7.76 vs. 0.10 ± 0.15 ng/mL, p < 0.001).
Concluded that S–PCT is superior to serum
CRP for detecting BM
[32] S–PCT Not reported Not reported Notreported
Not
reported
S–PCT is significantly higher in suppurative
meningitis and declined 72 h and 7 days after
treatment
[33] S–PCT Not reported 0.12 ng/mL 88.75% 74.14%
S–PCT > 0.12 ng/mL is useful for
differentiating BM vs. VM. S–PCT >
7.26 ng/mL associated with higher mortality
(OR = 9.09, 95% CI: 1.74–47.12, p = 0.016)
[34] CSFPCT 0.881 (0.810–0.932) 0.15 ng/mL 69.39 91.49%
CSF PCT levels are the most useful biomarker
for the diagnosis of BM
[34] S–PCT 0.759 (0.669–0.849) 0.19 ng/mL 67.35% 75.53% S–PCT is less useful than CSF PCT for thediagnosis of BM
4. Discussion
Procalcitonin, a precursor of calcitonin, is a 116 amino acid peptide and a member of the calcitonin
superfamily of peptides, with a molecular weight of 14.5 kDa. PCT is synthesized by the parafollicular
C cells of the thyroid gland and is involved in calcium homeostasis. In addition, PCT is also produced
by the neuroendocrine cells of the lung and the intestine. In the CNS, cells likely to be sources of
CSF PCT include the neurons, astrocytes, and microglia in the parenchyma and meningeal cells.
Normal S–PCT concentration is <0.05 ng/mL, with a reported half-life of 25–30 h [35]. Procalcitonin
is considered a sensitive and specific marker of certain bacterial infections, such as pneumonia,
meningitis, and pyelonephritis, and has been used as tool for the assessment of disease severity.
In addition to bacterial infections, increased PCT levels have been identified in other clinical conditions,
including severe fungal infections, trauma, burns, major surgery, and medical therapy that stimulates
cytokine production. In these cases, S–PCT levels are less elevated and rarely exceed 0.5 ng/mL [36].
There are several hypotheses regarding the pathophysiology of PCT; most suggesting that procalcitonin
may be involved in calcium metabolism, cytokine network, and the modulation of nitric oxide (NO)
J. Clin. Med. 2018, 7, 148 11 of 15
synthesis [37]. In sepsis, PCT hypersecretion emanates from multiple tissues throughout the body,
which are not traditionally viewed as endocrine tissues. It is likely that PCT in sepsis potentiates the
inflammation cascade by increasing leukocyte-derived cytokines and augmenting reactive oxygen
species [38]. PCT secretion is stimulated in bacterial infections by various cytokines, such as IL–1, IL–6,
and tumor necrosis factor-alpha. In contrast, PCT production is down-regulated in viral infections,
probably due to increased interferon gamma production. Consequently, PCT is considered a useful
tool for diagnosing sepsis and repeat S–PCT measurements over time can be used to monitor response
to therapy. Most currently used inflammatory markers do not reliably differentiate between a systemic
inflammatory response and sepsis. However, because PCT is, generally, not induced by severe viral
infections or non-infectious inflammatory reactions, PCT can help distinguish bacterial from viral
infections and differentiate between infectious and non-infectious origins of systemic inflammatory
response syndrome (SIRS), acute respiratory distress syndrome (ARDS), pancreatitis, cardiogenic
shock, and acute rejection of transplanted organs [39].
In CNS infections, disruption of the blood brain barrier (BBB) has been documented in patients
with bacterial infections and in experimental models [40,41]. Elevated CSF PCT levels in bacterial
meningitis patients seem to be the result of this mechanism and some studies have shown higher
CSF PCT levels in patients with Gram-negative bacteria compared to patients with Gram-positive
bacteria [42]. In CNS infection cases, microglia and meningeal cells express the responding
receptors (Toll-like receptors [TLRs]) to the invading bacteria [43]. Several questions regarding PCT
synthesis and secretion by brain cells during bacterial meningitis have not been resolved and need
further investigation.
Prompt diagnosis and appropriate antimicrobial treatment are of paramount importance and can
contribute to a reduced morbidity and mortality in sepsis. Procalcitonin is an acute-phase protein
with faster kinetics than C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and is
detectable in serum within 4–6 h after the onset of a bacterial infection. PCT serum levels peak within
24 h and start to decline by approximately 50% daily with effective treatment [44–46]. Although there
is no “gold standard” for the diagnosis of most infections, several biomarkers have been used as tools
to monitor disease progression. An ideal marker should help with early diagnosis and therapeutic
decision-making in bacterial infections and should also help clinicians assess the course and prognosis
and, in that regard, PCT seems to be superior compared to other commonly used biomarkers.
Despite advances in diagnosis and treatment, bacterial meningitis is a neurological emergency,
requires treatment in a high acuity care unit, and remains an important cause of mortality. The diagnosis
and management of bacterial meningitis requires various biological tests and a multidisciplinary
approach. Empiric antimicrobial and adjunctive therapy should start as soon as there is clinical
suspicion of meningitis. Regarding laboratory findings, a left shift in peripheral white blood cell count,
elevated serum PCT and C-reactive protein, CSF pleocytosis with predominance of polymorphonuclear
leukocytes, and decreased glucose concentration are predictive of bacterial meningitis. CSF analysis
is a gold standard for the diagnosis of meningitis: CSF gram staining reveals bacteria in 50% to
80% of cases and cultures are positive in 80% of cases, at best. However, the sensitivity of both
tests is <50% in patients already receiving antibiotics. CSF leukocyte count, protein, glucose and
lactate concentration, and a latex agglutination test adapted for the rapid direct detection of soluble
bacterial antigens in CSF lack the specificity and sensitivity for the diagnosis of meningitis and can
only define a clinical probability. In fact, the relatively imprecise nature of the cutoff values for these
markers can make their interpretation difficult. Furthermore, in the early phases of acute bacterial and
viral meningitis, differential diagnosis is difficult because signs and symptoms are often non-specific
and, therefore, differentiation between bacterial and viral meningitis remains a difficult problem for
clinicians. Biomarkers, like CRP, procalcitonin, or sTREM–1, may be useful for diagnosis and can help
differentiate between viral and bacterial meningitis [47,48]. Serum and CSF PCT levels can be more
useful in the diagnosis of bacterial meningitis and in distinguishing bacterial from viral meningitis.
A systematic review published by Markanday in 2015 compared serum PCT versus CRP as markers for
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bacterial infection and showed that, compared to CRP, S–PCT had a higher sensitivity and specificity
for differentiating bacterial from noninfectious causes of inflammation [49].
Diagnosis of meningitis requires a detailed history and physical examination combined with
high clinical suspicion and appropriate cultures. Prognosis of meningitis depends on rapid
diagnosis, identification of the cause, and prompt implementation of appropriate antibiotic treatment.
Because clinical and laboratory data available within a few hours after hospital admission are not
reliable (except for when bacteria are found in CSF under the microscope), use of biological markers
has been proposed as a tool to improve the accuracy of initial diagnosis and, in this setting, serum and
CSF procalcitonin measurements seem to be of great value. Because of its high specificity and positive
predictive value, elevated S–PCT concentrations (>0.5 ng/mL) indicates ongoing and, potentially,
severe systemic infection. Because C-reactive protein is the inflammatory marker most widely used
in emergency departments to discriminate bacterial from viral infections, Gerdes et al. published a
meta-analysis in 1998 from 35 studies aiming to assess the usefulness of CRP in discriminating bacterial
from viral meningitis. The meta-analysis showed that, although the majority of authors propose using
CRP as an additional tool for discriminating bacterial from viral meningitis, only negative CRP tests
are highly informative in most clinical settings [50]. However, procalcitonin seems to be a valuable
tool for discriminating the causative factor of meningitis as, since 1997 and 1998, two French studies
showed that, using a cut-off range of 0.5–2 ng/mL, S–PCT had 100% sensitivity and specificity in
discriminating bacterial from viral meningitis [51]. Similarly, a more recent meta-analysis published
by Vikse et al. in 2015 showed that procalcitonin has a 90% sensitivity and a 98% specificity in the
discrimination between bacterial and viral meningitis [26].
This review aims to provide clinicians with an overview of the role of S–PCT and CSF-PCT as
diagnostic markers in CNS infections. Several publications assessing the role of PCT as a guide for
antibiotic therapy in adult meningitis patients suggest that S–PCT is a sensitive, specific, and prognostic
marker of bacterial infections, therefore, S–PCT and CSF PCT measurement can help differentiate
bacterial from viral meningitis. Interpretation of PCT levels must take into consideration the clinical
presentation of the CNS infection. In addition, knowledge of assay characteristics is important for
setting specific cut-off values and functional assay sensitivities. Most clinical studies presented in
this review have limitations, including small sample sizes and inconsistent reporting of laboratory
findings: In some, AUC values and cut-off values were not reported, while a few were published
in languages other than English and, therefore, we only included in the review data reported in the
Abstract. Therefore, even though S–PCT seems to be a useful biomarker for the diagnosis and possible
prognosis in patients with BM, additional data from larger, well-designed studies are needed to better
evaluate the role of procalcitonin in the differentiation between viral and bacterial meningitis and as
tool to improve the overall management of patients with meningitis.
5. Conclusions
Serum PCT is a biomarker with high sensitivity and specificity in identifying patients with
sepsis and can be useful for the diagnosis of bacterial infections. This literature review identified
several studies evaluating the role of S–PCT in the assessment of patients with central nervous system
infections. Published data suggests that, compared to other acute phase biomarkers, S–PCT is superior
as a sepsis biomarker in acute meningitis and can help differentiate bacterial from viral meningitis.
Combined with good clinical judgment and appropriate use of antimicrobial agents, S–PCT could be a
valuable adjunct in the timely diagnosis and management of sepsis in patients with CNS infection.
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